Saturday 17 October 2026 Export TRDA’s income statement to Excel — free account

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.36 0.42 −8.79%

Follow TRDA

Alert me

Market cap: $186.1M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 3/9
Altman Z: 2.15
Beneish M: −6.07
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.64

Total sells 15.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	—	—	—	—	—	1	—	—	—	—	—
Sell	3	—	—	—	3	1	2	—	2	6	4	—

Insider Ownership 43.37%

Capital & Financial Ratios $m

Market Cap 186.12

Revenue 4.69

Net Income (165.78)

Free Cash Flow (134.35)

Net Debt (223.00)

Current Ratio 10.89

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.58)

P/S ratio 39.28

P/B ratio 0.79

Past 5Y EPS Growth —

This Y EPS Growth (11.89%)

Next Y EPS Growth 13.20%

Next Y revenue growth (52.13%)

Next 5Y EPS Growth 4.82%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 17.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	352	420	296	223
Receivables	6	4	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	370	440	306	233

	2023	2024	2025	Q'26
Payables	3	4	2	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	159	39	24	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	50.11%	12.93%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	21	2	2	1	25
’24	59	95	20	37	211

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(32)	—	—	—
’25	(39)	(29)	(28)	(32)	(129)
’24	(26)	40	(24)	(32)	(42)
’23	203	(35)	(24)	(4)	140
’22	(21)	(18)	(27)	(27)	(94)
’21	(8)	(8)	(14)	(21)	(51)
’20	—	—	(19)	(7)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(32)	—	—	—
’25	(40)	(30)	(28)	(32)	(130)
’24	(26)	39	(25)	(32)	(45)
’23	202	(37)	(26)	(5)	134
’22	(22)	(19)	(28)	(28)	(97)
’21	(9)	(9)	(15)	(22)	(55)
’20	—	—	(20)	(8)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.95)	(1.01)	—	—	—
’25	(0.42)	(1.04)	(1.06)	(0.94)	(3.47)
’24	0.68	1.55	(0.35)	0.03	1.68
’23	(0.21)	(0.78)	1.02	(0.29)	(0.20)
’22	(0.69)	(0.74)	(0.80)	(0.79)	(3.02)
’21	(6.67)	(7.56)	(9.78)	(0.89)	(8.16)
’20	—	—	(6.13)	—	(24.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	13.27	5.12	9.32	11.35	4.93	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	36.85	24.38	18.44	21.79	18.76
People
People	Employees	—	—	—	—	78	114	130	159	183	152
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.81	1.15	0.17
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	129	211	25
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	100.00	100.00	100.00
	EBT	—	—	—	(5)	(27)	(51)	(95)	12	66	(143)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	9.34	31.54	(561.84)
	Net income	—	0	—	(5)	(27)	(51)	(95)	(7)	66	(144)
	Depreciation	—	—	—	0	0	1	2	(3)	(6)	0
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	3.90	5.65	0.61
	Earnings	—	—	—	(5.47)	(24.00)	(8.16)	(3.02)	(0.20)	1.76	(3.47)
	Cash flow	—	—	—	(11.58)	(23.13)	(8.11)	(3.00)	4.23	(1.11)	(3.11)
	Capex	—	—	—	(0.68)	(2.10)	(0.73)	(0.09)	(0.17)	(0.08)	(0.03)
	Free cash flow	—	—	—	(12.25)	(25.23)	(8.85)	(3.09)	4.06	(1.20)	(3.13)
	Book value	—	—	—	17.47	36.34	47.66	6.79	7.33	11.49	7.40
	Shares, m	—	—	—	1	1	6	31	33	37	41
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	8.69	0.00
	P/S	—	—	—	—	—	—	—	3.89	3.06	16.73
	P/B	—	—	—	—	—	—	—	2.07	1.50	1.39
	EV/Sales	—	—	—	—	—	—	—	1.16	1.07	5.07
	EV/FCF	—	—	—	—	—	—	—	1.11	(5.03)	(1.00)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(11)	(26)	(51)	(94)	140	(42)	(129)
	Capex	—	—	—	(1)	(2)	(5)	(3)	(6)	(3)	(1)
	Free cash flow	—	—	—	(11)	(28)	(55)	(97)	134	(45)	(130)
Balance, $m
Balance, $m	Working capital	—	—	—	16	37	292	188	211	401	282
	Total debt	—	—	—	—	—	—	26	—	—	—
	Net debt	—	—	—	(17)	(39)	(291)	(189)	(352)	(420)	(296)
	Shareholders’ equity	—	—	—	16	40	299	213	242	429	306
Returns, %
Returns, %	ROA	—	—	—	(55.93)	(85.88)	(29.29)	(33.92)	(1.85)	13.18	(31.81)
	ROIC	—	—	—	0.00	(1,484.14)	(417.49)	(254.93)	0.00	338.50	(1,009.37)
	ROE	—	—	—	17.89	93.05	(39.78)	(37.01)	(2.94)	19.56	(39.13)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
STRO Sutro Biopharma, Inc.	$190.0M	— (loss-making)	— (loss-making)	−84.57% (below 0%: shrinking)	n/m	+14.55% (above 0%: growing)	100.00%	(303.77%)	Compare
YARW Yarrow Bioscience, Inc	$188.8M	— (loss-making)	— (loss-making)	+40.58% (above 0%: growing)	n/m	+81.56% (above 0%: growing)	100.00%	(3,197.94%)	Compare
TRDA Entrada Therapeutics, Inc.	$186.1M	— (loss-making)	— (loss-making)	−53.95% (below 0%: shrinking)	n/m	−9.10% (below 0%: shrinking)	100.00%	(5,007.02%)
UPB Upstream Bio, Inc.	$184.6M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
SION Sionna Therapeutics, Inc.	$184.5M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$181.4M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
Median of peers	$184.5M	—	—	−7.66%	—	+11.94%	100.00%	(217.90%)

All 614 Biotechnology stocks →

Entrada Therapeutics, Inc. (TRDA) key facts

Concern: Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
Entrada Therapeutics, Inc. (TRDA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TRDA traded at $4.36, a market capitalization of $186.1 million.
Return on equity was −39.1% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 2.15 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.